Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Wolfgang Richter

Ekkehard Moessner

Ralf Hosse

Pablo Umaña

Anne Freimoser-Grundschober

Christian Klein

Tilman Schlothauer

Inja Waldhauer

Alexander Knaupp

Halina Trochanowska

Thomas U Hofer

Valeria G Nicolini

Maria Valeria Gonzalez Nicolini

Hubert Kettenberger

Laurent Lariviere

Thomas Emrich

Thomas Kraft

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.

Antibody selection method

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

Growing community of inventors

Basel, Switzerland

Wolfgang Richter